ClinicalTrials.gg
CompletedNCT06311760Updated Feb 27, 2025

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants

A Phase 1 interventional study of AZD0292 and Placebo in Healthy Participants Study, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-27.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study will assess the safety, tolerability and pharmacokinetics (PK) of AZD0292 following intravenous (IV) administration of single ascending doses to healthy adult participants.

Read the detailed description

This is a First-time-in-human (FTiH) trial.

Eligible participants will be randomized to receive AZD0292 or Placebo. Participants will receive pre-medication with an antihistamine prior to dosing with the study intervention.

The study will comprise:

  1. A Screening Period of maximum 28 days.
  2. A Treatment Period
  3. A Follow-up Period from Day 3 to Day 16
  4. An extended Follow-up Period from Day 17 to Day 61

Participants will be involved in this study for a maximum duration of 13 weeks.

02

Conditions studied

  • Healthy Participants Study

Keywords

  • Monoclonal antibody
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All females must have a negative pregnancy test at screening and on admission to the Clinical Unit.
  • Females of must not be lactating and if heterosexually active, must agree to use an approved method of highly effective .
  • Have a (BMI) between 18 and 32 kilograms per meter square (kg/m\^2) inclusive and weigh at least 50 kilograms (kg) at screening.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which, in the opinion of the principal investigator (PI), may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
  • History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the previous 6 months prior to screening as well as individuals with a smoking history of tobacco greater than 5 pack years.
  • History of alcohol or drug abuse within the past 2 years that, according to the PI, might affect assessments of safety or ability of participant to comply with all study requirements.
  • Any drug therapy within 7 days prior to Day 1 (except , HRT, or a single use of acetaminophen, aspirin, antihistamine, or combination OTC product that contains acetaminophen with an antihistamine, or OTC nonsteroidal anti-inflammatory agent at a dose equal to or lower than that recommended on the package). Vitamins and other nutritional supplements that are not newly introduced, that is, have been taken for at least 30 days prior to enrollment, are not exclusionary.
  • Positive screen for drugs of abuse, alcohol, or cotinine at screening or on admission to the Clinical Unit.
  • Any abnormalities in clinical chemistry, hematology, coagulation, or urinalysis results.
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity.
  • Receipt of another new chemical entity (defined as a compound which has not been approved for marketing) within 30 days or 5 half-lives (whichever is longer) of the study intervention administration in this study. The period of exclusion begins one month after the final dose.
  • Receipt of any vaccine within 7 days prior to study intervention administration or planned receipt within 28 days after study intervention administration.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    AZD0292 Dose 1

    Participants will receive single dose of AZD0292 dose 1 as IV infusion on Day 1.

    Drug: AZD0292

  • Experimental
    AZD0292 Dose 2

    Participants will receive single dose of AZD0292 dose 2 as IV infusion on Day 1.

    Drug: AZD0292

  • Experimental
    AZD0292 Dose 3

    Participants will receive single dose of AZD0292 dose 3 as IV infusion on Day 1.

    Drug: AZD0292

  • Placebo comparator
    Placebo

    Participants will receive matching placebo to AZD0292 as IV infusion on Day 1.

    Drug: Placebo

Interventions

  • AZD0292 will be administered as single dose via IV infusion.

  • DrugPlacebo

    Placebo will be administered as IV infusion.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events

    The safety and tolerability of AZD0292 following IV administration of single ascending doses to healthy adult participants will be assessed.

    Time frame: Up to 13 weeks

  2. Number of Participants with Adverse Events of Special Interest (AESI)

    The safety and tolerability of AZD0292 following IV administration of single ascending doses to healthy adult participants will be assessed.

    Time frame: Up to 13 weeks

Secondary outcomes

  1. Maximum Observed Drug Concentration (Cmax)

    The PK (Cmax) of AZD0292 following IV administration of single ascending doses of AZD0292 to healthy adult participants will be assessed.

    Time frame: From Dosing (Day 1) to end of the study (up to 13 weeks)

  2. Area Under Concentration-Curve from Time Zero to the Last Quantifiable Concentration (AUClast)

    The PK (AUClast) of AZD0292 following IV administration of single ascending doses of AZD0292 to healthy adult participants will be assessed.

    Time frame: From Dosing (Day 1) to end of the study (up to 13 weeks)

  3. Area Under Concentration-Time Curve from Time Zero to Infinity (AUCinfinity)

    The PK (AUCinfinity) of AZD0292 following IV administration of single ascending doses of AZD0292 to healthy adult participants will be assessed.

    Time frame: From Dosing (Day 1) to end of the study (up to 13 weeks)

  4. Number of Participants with Positive Anti-drug Antibodies (ADAs)

    The ADA responses following IV administration of single ascending doses of AZD0292 to healthy adult participants will be evaluated.

    Time frame: From Dosing (Day 1) to end of the study (up to 13 weeks)

07

Study locations

1 site
  • Research Site
    Baltimore, Maryland 21225, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via there quest portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in Feb 2025, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2024
First posted
Mar 15, 2024
StartActual
Apr 9, 2024
Primary completionActual
Feb 20, 2025
CompletionActual
Feb 20, 2025
Last update
Feb 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06311760
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 15, 2024
Start date
Apr 9, 2024
Primary completion
Feb 20, 2025
Completion
Feb 20, 2025
Last update
Feb 27, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD0292

Start the discussion